Subject(s)
Anticonvulsants/adverse effects , Carbamazepine/analogs & derivatives , Depressive Disorder/drug therapy , Thrombocytopenia/chemically induced , Anticonvulsants/therapeutic use , Antidepressive Agents, Second-Generation/therapeutic use , Antipsychotic Agents/therapeutic use , Aripiprazole , Blood Cell Count/methods , Carbamazepine/adverse effects , Carbamazepine/therapeutic use , Cyclohexanols/therapeutic use , Depressive Disorder/blood , Depressive Disorder/psychology , Female , Humans , Middle Aged , Oxcarbazepine , Piperazines/therapeutic use , Quinolones/therapeutic use , Venlafaxine HydrochlorideABSTRACT
Transcranial magnetic stimulation (TMS), since its introduction in 1985, has been studied for its efficacy in different psychiatric disorders. It has been touted to be an effective treatment modality for major depression, obsessive compulsive disorder, Tourette syndrome, and in reducing auditory hallucinations in patients with schizophrenia. In this article, the authors outline the research and evidence toward the efficacy of TMS in psychiatry.
ABSTRACT
Post-traumatic stress disorder (PTSD) is a severe and disabling psychiatric syndrome. With the advent of selective serotonin reuptake inhibitors (SSRIs), major strides have been made in the realms of pharmacotherapy. The multiplicity of symptom complex includes specific target symptoms, such as intrusiveness, aggression, sleep disturbances, and co-existing psychotic symptoms. Consequently, atypical antipsychotics gradually have been gaining ground in terms of adjunctive utilization. The purpose of this review is to look into the available evidence for their adjunctive use in this chronic disorder.
